Updated on 4 August 2015
The Intellectual Property and Science business of Thomson Reuters announced the release of the 2015 CMR Pharmaceutical R&D Factbook, the biopharmaceutical industry's leading resource of global R&D trends.
Despite concerns around declines in R&D, the analysis identifies a surge in global sales with 2014's $1 trillion milestone and forecasts sales to reach $1.3 trillion by 2018. It also reveals a positive shift in new molecular entities (NMEs) with 46 launches in 2014; the highest in over a decade.
The study underscores a promising industry outlook with increases in sales and NME launches and with shifting trends in R&D pipeline volume and therapeutic areas as evidenced by these other key findings:
• Diversification increases NME launches: One third of 2014 launches were for rare indications, mainly within Anti-cancer. More than 65 percent were specialty drugs for the treatment of Anti-cancer, Hepatitis C Virus and HIV.
• Anti-cancer dominates: Anti-cancer development continues to attract the highest amount of investments across all therapeutic areas; with the majority of recent launches receiving orphan drug status from regulatory authorities.